Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Human clinical trial data remains limited, with Phase I and II trials for inflammatory bowel disease conducted in the 1990s claiming safety with no toxicity, though full peer-reviewed data never appeared in scientific literature
Berger H, Wodarz A, Borchers A
Biochemistry 47 , 14521463 (2008)
CNS Drugs (2019) 33(3):20923
STEP 1 (Wilding et al., 2021, New England Journal of Medicine) enrolled 1,961 participants and demonstrated a mean body weight reduction of 14.9% at 68 weeks with 2.4mg subcutaneous semaglutide, the first pharmacological intervention to produce weight loss of this magnitude in a Phase 3 trial, establishing a new efficacy benchmark that became the comparison standard for all subsequent metabolic compounds including Tirzepatide and Retatrutide
US$ 21.70
US$ 25.44
US$ 27.67
US$ 28.93
